Bioventus Inc. 是一家醫療器械公司,專注於在美國及國際間開發及商業化涉及並增強人體自然癒合過程的臨床治療。公司總部位於北卡羅來納州達勒姆。
財務指標
營業收入
2026-06-30
$153.2M
2026-03-31
$132.08M
2025-12-31
$157.9M
2025-09-30
$138.65M
營業支出
2026-06-30
$86.53M
2026-03-31
$80.77M
2025-12-31
$85.77M
2025-09-30
$80.72M
淨利潤
2026-06-30
$33.44M
2026-03-31
$3.11M
2025-12-31
$14.75M
2025-09-30
$3.15M
淨利潤率
2026-06-30
21.82%
2026-03-31
2.35%
2025-12-31
9.34%
2025-09-30
2.27%
每股收益
2026-06-30
$0.22
2026-03-31
$0.15
2025-12-31
$0.24
2025-09-30
$0.15
息稅折舊攤銷前利潤
2026-06-30
$30.32M
2026-03-31
$20.04M
2025-12-31
$31.14M
2025-09-30
$22.25M
有效稅率
2026-06-30
-136.51%
2026-03-31
12.64%
2025-12-31
-22.44%
2025-09-30
14.21%
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$153.2M
$132.08M
$157.9M
$138.65M
營業支出
$86.53M
$80.77M
$85.77M
$80.72M
淨利潤
$33.44M
$3.11M
$14.75M
$3.15M
淨利潤率
21.82%
2.35%
9.34%
2.27%
每股收益
$0.22
$0.15
$0.24
$0.15
息稅折舊攤銷前利潤
$30.32M
$20.04M
$31.14M
$22.25M
有效稅率
-136.51%
12.64%
-22.44%
14.21%
常見問題
BVS stock refers to the publicly traded shares of a company that uses the ticker symbol BVS. The ticker is the short identifier investors type into brokerage platforms and financial websites to access real-time quotes, charts, and company filings. Because BVS is a specific U.S.-listed security, its profile page provides the most current details on the underlying business, exchange listing, and market data. Investors can use that page to confirm the exact company represented by BVS before researching further.
The industry classification for BVS depends on the company behind the ticker and is typically listed in its stock profile and regulatory filings. Sector and industry labels help investors compare BVS with peers, understand its business model, and assess sector-specific risks. The most accurate and current industry designation for BVS is shown on the stock detail page, where it is grouped alongside other companies in the same line of business.
Recent performance for BVS is best measured using the latest price change, percentage move, and short-term chart shown on its stock detail page. These figures update throughout the trading day, so any specific number quoted here could quickly become outdated. Investors often compare BVS's recent return with relevant market indexes and sector peers to judge relative strength, but the most reliable current performance data is the live quote displayed for BVS.
Evaluating BVS's valuation involves reviewing metrics such as the price-to-earnings ratio, price-to-sales ratio, price-to-book ratio, and enterprise value relative to EBITDA. These figures are most useful when compared with BVS's own historical averages and with industry peers. Because valuation multiples change with price and earnings, the current metrics for BVS should be taken from the stock detail page rather than assumed. The goal is to judge whether the market price reflects the company's financial fundamentals.
Risks for BVS include company-specific factors such as competitive pressure, execution challenges, leverage, and dependence on key products or customers. Broader risks may include sector downturns, regulatory changes, interest rate shifts, and general market volatility. Because BVS operates in a particular industry, its risk profile also reflects that industry's cycles and cost structure. Investors can review BVS's risk factor disclosures and financial statements for a fuller picture of these potential threats.
Researching BVS starts with its stock detail page, which consolidates price data, performance charts, valuation metrics, and company information. Investors can then review BVS's quarterly and annual reports, earnings releases, and investor presentations for financial statements and management commentary. Comparing BVS with industry peers and tracking news that affects its sector can add context. Using several sources helps build a balanced view rather than relying on a single data point.